More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$21.06B
EPS
11.29
P/E ratio
24.8
Price to sales
1.53
Dividend yield
1.121%
Beta
0.882177
Previous close
$260.06
Today's open
$260.23
Day's range
$255.83 - $260.92
52 week range
$241.81 - $293.72
show more
CEO
Adam H. Schechter
Employees
70000
Headquarters
Burlington, NC
Exchange
New York Stock Exchange
Shares outstanding
82000000
Issue type
Common Stock
Healthcare
Medical Diagnostics & Screening
LH Expands Genetic Testing in CRC Through New Collab: Stock to Gain?
Labcorp joins a national CRC trial as exclusive genetic testing provider, expanding Invitae-based testing and supporting cancer research.
Zacks Investment Research • Jun 1, 2026

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members Research will also assess the clinical impact of broader genetic testing in colorectal cancer care BURLINGTON, N.C., May 29, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (CRC).
PRNewsWire • May 29, 2026

Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects
New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatment BURLINGTON, N.C., May 28, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of its expanded DPYD Genotyping test to help identify cancer patients who may be at increased risk for severe or life-threatening side effects from fluoropyrimidine chemotherapy.
PRNewsWire • May 28, 2026

Labcorp to Present at the Jefferies Global Healthcare Conference
BURLINGTON, N.C., May 27, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, from 12:15 pm to 12:45 pm ET.
PRNewsWire • May 27, 2026

LH or MEDP: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical Services sector might want to consider either Labcorp Holdings (LH) or Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
Zacks Investment Research • May 27, 2026

Should You Continue to Hold Labcorp Stock in Your Portfolio?
LH gains from specialty testing growth, acquisitions and AI initiatives, but currency swings and macro pressures remain risks.
Zacks Investment Research • May 22, 2026

Labcorp (LH) Upgraded to Buy: Here's What You Should Know
Labcorp (LH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research • May 22, 2026

Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over Time
MyLabcorp connects lab results, educational content and AI-enabled features in a secure, personalized mobile experience Leverages OpenAI models designed to help users understand their results, ask questions and identify patterns over time BURLINGTON, N.C., May 20, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of MyLabcorp ™ , an AI-powered mobile app that brings together lab results, AI-enabled features and clinical guideline-based content in a secure, personalized mobile experience.
PRNewsWire • May 20, 2026

Why Labcorp Holdings (LH) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research • May 20, 2026

Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems
Labcorp's full test menu will be available through Epic's Aura platform Integration builds on the successful deployment of Invitae genetic testing and accelerates access to the latest genetic and specialty diagnostics through Aura Collaboration will help reduce IT complexity, streamline lab ordering and improve access to diagnostic innovation for hospitals and health systems using Epic nationwide BURLINGTON, N.C., May 12, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with Epic, the nation's leading electronic health record (EHR) supporting hospitals and health systems.
PRNewsWire • May 12, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Labcorp Holdings Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.